Harvard Apparatus Regenerative Technology Inc. (HRGN)

2.6800 +0.4800 (+21.82%) At close: 03:40PM EDT

Harvard Apparatus Regenerative Technology Inc.

84 October Hill Road
Suite 11
Holliston, MA 01746
United States
774 233 7300
https://hregen.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 18

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Junli He	CEO & Chairman	483.11k	N/A	1974
Mr. Yu Hong	President	189.06k	N/A	1973
Mr. Joseph L. Damasio Jr.	Chief Financial Officer	266.04k	N/A	1974
Dr. William L. Fodor Ph.D.	Chief Scientific Officer	245.06k	N/A	1959
Dr. Shunfu Hu Ph.D.	Vice President of Business Development & Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company also sells Longevity products that focuses on personal healthcare, including longevity dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.

Corporate governance

Harvard Apparatus Regenerative Technology Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.